- Home
- NIVF vs ATNF Comparison
NIVF vs ATNF Comparison
Compare NIVF & ATNF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIVF
- ATNF
- Stock Information
- Founded
- NIVF 2011
- ATNF 2016
- Country
- NIVF Hong Kong
- ATNF United States
- Employees
- NIVF N/A
- ATNF N/A
- Industry
- NIVF
- ATNF Biotechnology: Pharmaceutical Preparations
- Sector
- NIVF
- ATNF Health Care
- Exchange
- NIVF NYSE
- ATNF Nasdaq
- Market Cap
- NIVF 3.9M
- ATNF 4.1M
- IPO Year
- NIVF N/A
- ATNF N/A
- Fundamental
- Price
- NIVF $2.11
- ATNF $1.25
- Analyst Decision
- NIVF
- ATNF
- Analyst Count
- NIVF 0
- ATNF 0
- Target Price
- NIVF N/A
- ATNF N/A
- AVG Volume (30 Days)
- NIVF 2.6M
- ATNF 84.0K
- Earning Date
- NIVF 02-16-2025
- ATNF 03-04-2025
- Dividend Yield
- NIVF N/A
- ATNF N/A
- EPS Growth
- NIVF N/A
- ATNF N/A
- EPS
- NIVF N/A
- ATNF N/A
- Revenue
- NIVF $5,679,218.00
- ATNF N/A
- Revenue This Year
- NIVF N/A
- ATNF N/A
- Revenue Next Year
- NIVF N/A
- ATNF $54.15
- P/E Ratio
- NIVF N/A
- ATNF N/A
- Revenue Growth
- NIVF N/A
- ATNF N/A
- 52 Week Low
- NIVF $0.11
- ATNF $1.16
- 52 Week High
- NIVF $17.24
- ATNF $17.75
- Technical
- Relative Strength Index (RSI)
- NIVF 76.40
- ATNF 33.17
- Support Level
- NIVF $1.85
- ATNF $1.31
- Resistance Level
- NIVF $2.89
- ATNF $1.38
- Average True Range (ATR)
- NIVF 0.30
- ATNF 0.06
- MACD
- NIVF 0.18
- ATNF 0.01
- Stochastic Oscillator
- NIVF 72.03
- ATNF 0.00
About NIVF NEWGENIVF GROUP LIMITED
NewGenIvf Group Ltd is a company engaged in providing assisted reproductive services in Asia Pacific with a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely first which is a in-vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and surrogacy and ancillary caring services.
About ATNF 180 Life Sciences Corp.
180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research, and, where appropriate, combination therapy.